Presentations Verve Therapeutics Presentation at the 41st Annual J.P. Morgan Healthcare Conference AHA 2022 presentation on VERVE-101 ESC 2022 Poster: Nomination of VERVE-201 ANGPTL3 Product Candidate ESC 2022 Investor Presentation: Nomination of VERVE-201 ANGPTL3 Product Candidate ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene ASGCT 2022 presentation TIDES 2022: In Vivo CRISPR Base Editing to Treat ASCVD Keystone Symposia 2022: Off-target Analyses ACC 2022: Sequential in vivo CRISPR base editing of the PCSK9 and ANGPTL3 genes in NHPs In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia Pagination Current page 1 Page 2 Next page next › Last page last »
Verve Therapeutics Presentation at the 41st Annual J.P. Morgan Healthcare Conference AHA 2022 presentation on VERVE-101 ESC 2022 Poster: Nomination of VERVE-201 ANGPTL3 Product Candidate ESC 2022 Investor Presentation: Nomination of VERVE-201 ANGPTL3 Product Candidate ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene ASGCT 2022 presentation TIDES 2022: In Vivo CRISPR Base Editing to Treat ASCVD Keystone Symposia 2022: Off-target Analyses ACC 2022: Sequential in vivo CRISPR base editing of the PCSK9 and ANGPTL3 genes in NHPs In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia Pagination Current page 1 Page 2 Next page next › Last page last »
ASGCT 2022 poster: Comprehensive evaluation for off-target editing of in vivo base editing medicines targeting the PCSK9 gene
In vivo CRISPR base editing of ANGPTL3 in a non-human primate model of homozygous familial hypercholesterolemia